Jasper Therapeutics, Inc. (NASDAQ:JSPR - Free Report) - Equities research analysts at William Blair issued their Q1 2026 earnings per share (EPS) estimates for shares of Jasper Therapeutics in a research note issued to investors on Thursday, February 27th. William Blair analyst M. Phipps anticipates that the company will post earnings per share of ($1.14) for the quarter. The consensus estimate for Jasper Therapeutics' current full-year earnings is ($4.47) per share. William Blair also issued estimates for Jasper Therapeutics' Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.20) EPS, Q4 2026 earnings at ($1.22) EPS and FY2028 earnings at ($3.90) EPS.
Jasper Therapeutics (NASDAQ:JSPR - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($1.62) earnings per share for the quarter, missing the consensus estimate of ($1.27) by ($0.35).
A number of other analysts have also recently weighed in on JSPR. HC Wainwright cut their price target on Jasper Therapeutics from $60.00 to $40.00 and set a "buy" rating on the stock in a research note on Friday, January 10th. JMP Securities reissued a "market outperform" rating and set a $70.00 target price on shares of Jasper Therapeutics in a research report on Monday, January 6th. Royal Bank of Canada lowered their price target on Jasper Therapeutics from $68.00 to $48.00 and set an "outperform" rating for the company in a report on Thursday, January 9th. BMO Capital Markets began coverage on shares of Jasper Therapeutics in a report on Friday, December 6th. They set an "outperform" rating and a $63.00 price objective on the stock. Finally, UBS Group initiated coverage on shares of Jasper Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $38.00 price objective for the company. Eleven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus price target of $64.44.
Read Our Latest Report on Jasper Therapeutics
Jasper Therapeutics Price Performance
Shares of Jasper Therapeutics stock traded down $0.36 during trading on Monday, hitting $5.33. 156,527 shares of the stock were exchanged, compared to its average volume of 685,587. The firm's 50-day moving average price is $8.67 and its 200 day moving average price is $16.48. The stock has a market cap of $79.88 million, a price-to-earnings ratio of -1.13 and a beta of 2.11. Jasper Therapeutics has a 12-month low of $4.55 and a 12-month high of $31.01.
Institutional Trading of Jasper Therapeutics
A number of large investors have recently bought and sold shares of JSPR. Rhumbline Advisers increased its stake in Jasper Therapeutics by 12.6% in the fourth quarter. Rhumbline Advisers now owns 14,761 shares of the company's stock valued at $316,000 after purchasing an additional 1,652 shares during the period. BNP Paribas Financial Markets increased its position in Jasper Therapeutics by 208.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,512 shares of the company's stock valued at $47,000 after acquiring an additional 1,698 shares during the period. Barclays PLC raised its stake in Jasper Therapeutics by 13.6% during the 4th quarter. Barclays PLC now owns 18,334 shares of the company's stock valued at $392,000 after acquiring an additional 2,188 shares during the last quarter. Wellington Management Group LLP raised its stake in Jasper Therapeutics by 13.9% during the 4th quarter. Wellington Management Group LLP now owns 27,069 shares of the company's stock valued at $579,000 after acquiring an additional 3,310 shares during the last quarter. Finally, Fernwood Investment Management LLC lifted its position in Jasper Therapeutics by 6.9% during the 3rd quarter. Fernwood Investment Management LLC now owns 52,897 shares of the company's stock worth $995,000 after acquiring an additional 3,427 shares during the period. Institutional investors and hedge funds own 79.85% of the company's stock.
About Jasper Therapeutics
(
Get Free Report)
Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.
Featured Articles
Before you consider Jasper Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jasper Therapeutics wasn't on the list.
While Jasper Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
